DBV Technologies to Highlight Viaskin Technology Platform at the 2018 AAAAI/WAO Joint Congress

Press ReleaseMontrouge, France, February 12, 2018 DBV Technologies to Highlight Viaskin Technology Platform at the 2018 AAAAI/WAO Joint Congress                                                                                                                                                                               DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced that the Company will present data highlighting its Viaskin technology platform at the 2018 American Academy of Allergy, Asthma & Immunology (AAAAI)/World Allergy Organization (WAO) Joint Congress Meeting in Orlando, Florida, March 2 - 5, 2018. The abstracts became available on the AAAAI/WAO Joint Congress website at 9:00 AM ET on February 12. Four abstracts have been accepted for poster presentation, including a late-breaking abstract on the topline results from the Company's PEPITES (Peanut EPIT Efficacy and Safety) Phase III trial. These results were previously released by the Company in October 2017. The PEPITES trial evaluated the safety and efficacy of Viaskin Peanut in children four to 11 years of age."As we head into AAAAI/WAO, we are excited to once again present data and discuss the PEPITES topline results with the medical community," said Dr. Pierre-Henri Benhamou, Chairman & Chief Executive Officer of DBV Technologies. "Viaskin Peanut has been granted Fast Track and Breakthrough Therapy Designation by the FDA, and we look forward to offering this treatment to patients as soon as possible, if approved."Presentation and abstract details are as follows:Viaskin Peanut Clinical Data "Effect of epicutaneous immunotherapy on inducing peanut desensitization of peanut-allergic children: topline peanut epicutaneous immunotherapy efficacy and safety (PE ...